Treatment Registry
TR-0815 ActiveRecorded September 3, 2026

Brand tirzepatide

Sold by MEDGm · every brand tirzepatide record

The register has not established whether this program ships a vial, a pen, or another form. That is a gap in our record, not a statement about the company.

Price

No price with a verifiable quote was recorded at this reading.

Enroll with MEDGm

This is a paid link. If you enroll through it, Treatment Registry may earn a commission. It does not change what we record, and it does not change the price you pay.

History

One reading so far. A price history appears here after the next verification pass.

  • September 3, 2026Entry added to the register

Sourcing and terms

PharmacyNot disclosed
StatesNot disclosed
PrescriberBoth
Cancellation“The Subscription Service fee is charged upfront for the contracted term you selected and is non-refundable, except for the exceptions specifically identified in the Refund Policy below.”
MembershipRequired. $99, over a period the company does not state. “$99 MEMBERSHIP + COST · Zepbound® Injection”
Consult feeNot disclosed

Recorded from medgm.org. Unlike the price rows above, these carry a summary rather than a word-for-word quotation, so they are not shown in quotation marks.

Notes

  1. 1. September 3, 2026MEDGm sells Zepbound® as “$99 MEMBERSHIP + COST”: the membership carries a price and the medication is billed on top of it. The $99 buys access to the program, not the drug, so a reader setting it beside an all-in monthly program is not comparing like with like. MEDGm attaches no period to the membership figure either.

6 further notes concern other MEDGm programs and sit on the provider record.

Treatment Registry is an independent editorial record. It is not a government registry, a licensing body, or a certification. An entry means we recorded what a company published on a given date. It does not mean we recommend the program, and it does not mean the program is approved by anyone.

This record

Entry
TR-0815
Readings
1

Related records

Cite this entry

Treatment Registry. (2026). MEDGm brand tirzepatide (TR-0815). Last verified September 3, 2026. Retrieved [your access date], from https://treatmentregistry.com/registry/TR-0815

Replace the bracket with the date you read it. Ours is the date we last checked the figures, which is a different thing and is given separately.